Vergoeding 2017-2021 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Abasaglar ®) | 46.567.900 | 43.865.900 | 41.164.100 | 39.586.600 | 33.870.300 |
| A10AE05 Insuline detemir (Levemir ®) | 14.744.500 | 12.206.700 | 10.395.100 | 8.986.600 | 7.401.400 |
| A10AE06 Insuline degludec (Tresiba ®) | 13.313.200 | 18.504.900 | 19.282.400 | 19.547.700 | 19.733.600 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | 85.617 | 428.860 | 657.230 | 451.990 | 346.440 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | 1.570.500 | 3.567.700 | 3.521.700 | 2.860.600 | 2.203.000 |
| Totaal | 76.281.717 | 78.574.060 | 75.020.530 | 71.433.490 | 63.554.740 |